Alps Group Inc

Alps Group Inc reported its fiscal year 2026 financial results, with revenue growing 44% to $4.9 million, driven by cellular therapy, medical testing, and healthcare products. The company's net loss improved to $2.1 million from $2.6 million in the prior year, though gross margin decreased to 32%. Key business highlights include its Nasdaq listing in October 2025, advancements in its cellular therapy pipeline, and expanded laboratory accreditation for Whole Genome Sequencing.

Alps Group Inc reported its financial results for the fiscal year ended March 31, 2026, with revenue growing 44% to $4.9 million, driven by cellular therapy, medical testing, and healthcare products. The company's net loss improved to $2.1 million from $2.6 million year-over-year. Fiscal year 2026 was transformational, marked by its Nasdaq Global Market listing in October 2025, significant advancements in its cellular therapy pipeline, and strategic leadership appointments.

Alps Group Inc announced its expansion into patient-derived organoid (PDO) technology through a Research and Collaboration Agreement with Axiocell Biotech. The company is launching an internal PDO program focused on personalized cancer treatment and preclinical drug screening, aiming to develop Malaysia’s first clinically validated PDO platform. This move positions Alps in a rapidly growing market, with the global human organoids market projected to reach $349.5 million by 2036 and the personalized cancer treatment market $332.37 billion by 2030.

Alps Group Inc announced that its subsidiary, MyGenome Sdn. Bhd., has received MS ISO 15189:2022 accreditation for Whole Genome Sequencing (WGS). This internationally recognized clinical standard validates MyGenome's genomic data for accuracy, reproducibility, and reliability, positioning it among a select group of genomics laboratories in Southeast Asia. The accreditation expands Alps' addressable market to include government-linked healthcare programs, cross-border partnerships, and institutional clients, strengthening its position in Southeast Asian genomics.

Alps Group Inc. announced that its subsidiary, MyGenome Sdn. Bhd., received MS ISO 15189:2022 accreditation for its Whole Genome Sequencing (WGS). This internationally recognized clinical standard validates MyGenome's genomic data for accuracy, reproducibility, and reliability in clinical use and research. The accreditation expands Alps' addressable market to include government-linked healthcare programs and institutional clients across Southeast Asia, positioning MyGenome among a select group of genomics laboratories in the region.

Alps Group Inc announced it received a notification from The Nasdaq Stock Market LLC for non-compliance with the minimum bid price requirement. The company's ordinary shares traded below $1.00 for 30 consecutive business days. This notification does not immediately affect the listing or trading of its shares, and Alps Group has until November 11, 2026, to regain compliance. The company is evaluating options to address the deficiency and intends to comply, though there is no assurance of success.

Alps Group Inc. announced it received a letter from Nasdaq on May 15, 2026, notifying the company of non-compliance with the minimum bid price requirement of $1.00 per share for 30 consecutive business days. The company has 180 calendar days, until November 11, 2026, to regain compliance. This notification does not immediately affect the listing or trading of its shares or its business operations, and the company is evaluating options to cure the deficiency.